# Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression

> **NCT01284517** · PHASE3 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 356 (actual)

## Conditions studied

- Bipolar Depression

## Interventions

- **DRUG:** Lurasidone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01284517
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 356 (ACTUAL)
- **Last updated:** 2013-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01284517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01284517, "Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01284517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*